30 April 2012

Group II Part V: S. Nikkho: Composite Endpoints

All credits to Sylvia Nikkho, Bayer Pharma AG, Berlin, Germany

Presentation at the 2nd PVRI/FDA Conference, Bethesda, Washington DC, April 30-May 1st 2012


Additional key-words:  functional class,follow-up,clinical trials

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI